Antiglaucoma Medications

Key Points

• Chronic primary open-angle glaucoma (POAG) management centers on sustained intraocular pressure (IOP) reduction to slow optic-nerve damage.
• Acute angle-closure glaucoma is an emergency: severe eye pain/headache with rapid IOP rise can cause permanent vision loss within 24-48 hours.
• First-line topical classes for POAG include beta blockers, alpha-2 adrenergic agonists, and prostaglandin analogues; carbonic anhydrase inhibitors are common adjuncts.
• Rho kinase inhibitors are additional topical options that increase trabecular outflow.
• Combination therapy is often required because drug classes lower IOP through different mechanisms.

Clinical Use Framework

Antiglaucoma drugs lower IOP by either decreasing aqueous-humor production or increasing aqueous outflow. POAG treatment is long-term and often asymptomatic, so adherence and follow-up pressure checks are central nursing priorities.

In acute angle-closure pathways, medications are used rapidly to lower IOP and stabilize symptoms before definitive procedural/surgical management.

Drug Classes and Typical Dosing Patterns

Class	Representative Agents	Typical Adult Ophthalmic Pattern	Core Action
Beta-adrenergic blockers	Timolol, betaxolol, carteolol	Usually 1 drop once or twice daily depending on product	Decrease aqueous production
Prostaglandin analogues	Latanoprost, bimatoprost, travoprost	1 drop in affected eye(s) once nightly	Increase aqueous outflow (uveoscleral/trabecular pathways)
Alpha-2 adrenergic agonists	Brimonidine; brimonidine/timolol combination	Often 1 drop every 8 hours (product-dependent)	Decrease aqueous production and increase outflow
Carbonic anhydrase inhibitors	Dorzolamide, brinzolamide	Usually 1 drop 2-3 times daily (regimen-dependent)	Decrease aqueous production
Rho kinase inhibitors	Netarsudil	1 drop in affected eye(s) each evening	Increase trabecular outflow

Adverse Effects and Contraindications

• Beta blockers: bradycardia, hypotension, heart block, bronchospasm; avoid in severe asthma/COPD, sinus bradycardia, advanced AV block, severe heart failure, cardiogenic shock.
• Prostaglandin analogues: ocular hyperemia, stinging, blurred vision, eyelash growth and periocular/iris pigmentation changes; avoid in active intraocular inflammation.
• Alpha-2 agonists: fatigue/dizziness, hypotension or heart-rate changes, reduced alertness, ocular irritation/allergic conjunctivitis; contraindicated in children younger than 2 years.
• Carbonic anhydrase inhibitors: burning/stinging, bitter taste, conjunctival irritation, potential metabolic acidosis/electrolyte disturbance risk in vulnerable clients; severe sulfonamide hypersensitivity reactions are possible.
• Rho kinase inhibitors: conjunctival hyperemia/hemorrhage, instillation discomfort, increased tearing, corneal verticillata, temporary visual blurring.

Nursing Assessment and Interventions

• Assess baseline ocular status and reinforce scheduled IOP follow-up with ophthalmology.
• Review cardiopulmonary history before topical beta-blocker use and monitor heart rate, blood pressure, breathing status, and fatigue patterns.
• Assess fall risk and orthostatic symptoms, especially in older adults and in alpha-2 agonist pathways.
• In clients with diabetes, monitor for possible masking of adrenergic hypoglycemia cues when topical beta blockers are used.
• In renal impairment pathways, monitor for metabolic-acidosis or electrolyte-risk cues with carbonic anhydrase inhibitors.
• Reinforce punctal (medial canthus) occlusion for about 1-2 minutes after instillation to reduce systemic absorption.
• Maintain a safe environment when transient blurred vision or dizziness affects mobility.

Client Education

• Use drops exactly as prescribed even when symptoms are minimal.
• Keep all follow-up appointments for pressure checks and progression surveillance.
• Remove contact lenses before administration and wait about 15 minutes before reinsertion when instructed.
• Report severe eye pain, vision decline, persistent redness/swelling, dyspnea, wheezing, syncope, or palpitations promptly.
• Avoid driving or hazardous activity until visual clarity and alertness are adequate after instillation.
• If multiple drops are prescribed, separate administrations by about 5-10 minutes to reduce washout.
• Do not stop therapy without prescriber guidance.

Related Concepts

• eye-assessment-visual-acuity-and-common-abnormalities - Ongoing visual-acuity and ocular-change surveillance.
• ophthalmic-medication-administration - Safe instillation technique and contamination prevention.
• beta-blockers - Systemic and ophthalmic beta-blocker safety overlap.
• alpha-2-agonists - Adrenergic-agonist hemodynamic and CNS monitoring overlap.
• muscarinic-agonists - Additional glaucoma-related miotic pathways.